Hudson Bay Capital Management
ENVB icon

Hudson Bay Capital Management’s Enveric Biosciences ENVB Stock Holding History

Hudson Bay Capital Management’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-61
Closed -$46K – 1026
2022
Q3 		$46K Sell
61
-447
-88% -$563K ﹤0.01% 982
2022
Q2 		$980K Sell
508
-23
-4% -$48.9K 0.01% 933
2022
Q1 		$1.58M Buy
+531
New +$2.35M 0.02% 748
2018
Q4 		– Sell
-1
Closed -$1.24M – 807
2018
Q3 		$1.24M Buy
+1
New +$1.29M 0.02% 548

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hudson Bay Capital Management's ENVB Position: Q4 2022 in Review

Hudson Bay Capital Management sold out of Enveric Biosciences (ENVB) in Q4 2022, closing a stake of 61 shares — an estimated $46K sold.

Hudson Bay Capital Management first reported a position in ENVB in Q3 2018 and held it in 4 quarters. The position peaked at $1.58M in Q1 2022. 9 funds tracked by Wall St. Rank hold ENVB as of Q4 2022.

  • Hudson Bay Capital Management reported no remaining Enveric Biosciences position as of Q4 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 61 Enveric Biosciences shares in Q4 2022, an estimated $46K.
  • Hudson Bay Capital Management first reported a position in Enveric Biosciences in Q3 2018 and held it in 4 quarters.
  • Hudson Bay Capital Management's Enveric Biosciences position peaked at $1.58M in Q1 2022.
  • 9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q4 2022.

Based on Hudson Bay Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.